A deal with SUDA and Pfizer could look something like this. Old news and a different company and product but something similar could put a rocket under the share price. Just substitute Suda for Santartis.
Under the terms of the expanded agreement, Pfizer will make a payment of $14 million for access to Santaris Pharma A/S LNA technology for the development of RNA-targeted drugs. Santaris Pharma A/S is eligible to receive milestone payments of up to $600 million as well as royalties on sales of products that may be developed for up to 10 new RNA targets selected by Pfizer.
Those interested in reading the full article can click the link below.
http://www.biospace.com/News/santaris-pharma-a-s-announces-expanded-worldwide/206444
Artimist, page-16
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $216.7M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.3¢ | $183.7K | 897.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 955433 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 15.59pm 15/11/2024 (20 minute delay) ? |
| ALA (ASX) Chart |